Today marks a significant advancement in the microphysiological systems (MPS) sector with the establishment of IAMPS – the Industry Alliance for Microphysiological Systems. This groundbreaking initiative, spearheaded by MIMETAS and supported by eight other innovative companies, aims to propel MPS technologies into the forefront of drug development. The alliance includes key players such as AlveoliX, BiomimX, and InSphero, among others, collectively focusing on enhancing organoid and organ-on-chip technologies that promise more ethical and efficient alternatives to traditional models.
IAMPS is set to play a crucial role in fostering regulatory acceptance and standardization of MPS technologies, which are essential for the future of drug discovery. By advocating for strategic investments and improving access to biobanking resources, the alliance aims to broaden the adoption of MPS within both regulatory frameworks and the pharmaceutical industry. The leadership of IAMPS, including President Thibault Honegger and Vice-President Paola Occhetta, underscores the coalition’s commitment to establishing harmonized standards that will facilitate the integration of MPS into mainstream drug development practices.
Jos Joore, CEO of MIMETAS, emphasized the transformative potential of MPS technologies, stating that they are crucial for developing human-relevant therapies. As MIMETAS continues to lead in organ-on-a-chip innovations, the formation of IAMPS represents a pivotal moment for the industry, promising to enhance the scientific rigor and safety of drug development processes globally.
Start your 7-day trial and see what the database can do →
